oxazoles has been researched along with dinaciclib in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Giordano, A; Morales, F | 1 |
Boikos, SA; Dozmorov, MG; E Koblinski, J; Faber, AC; Fairchild, CK; Floros, KV; Hu, B; Jacob, S; Kurupi, R; Puchalapalli, M; Scaltriti, M | 1 |
1 review(s) available for oxazoles and dinaciclib
Article | Year |
---|---|
Overview of CDK9 as a target in cancer research.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cyclic N-Oxides; Cyclin-Dependent Kinase 9; Flavonoids; Humans; Indolizines; Molecular Targeted Therapy; Neoplasms; Oxazoles; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridinium Compounds; Roscovitine; Thiazoles; Urea | 2016 |
1 other study(ies) available for oxazoles and dinaciclib
Article | Year |
---|---|
Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cyclic N-Oxides; Drug Synergism; Female; Gene Amplification; Humans; Indoles; Indolizines; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Oxazoles; Protein Kinase Inhibitors; Pyridines; Pyridinium Compounds; Quinazolines; Quinolines; Random Allocation; Receptor, ErbB-2; Sulfonamides; Xenograft Model Antitumor Assays | 2021 |